Skip to content

Immunome IMNM Return on invested capital

Return on invested capital at other companies

Pfizer logo
PfizerPFE
6%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-95.3%+1.8pp
Nuvation Bio logo
Nuvation BioNUVB
-47.4%-18.6pp
SELLAS Life Sciences Group, Inc. logo
SELLAS Life Sciences Group, Inc.SLS
-4,437.7%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
-21.2%-6.9pp
Summit Therapeutics logo
Summit TherapeuticsSMMT
-81.8%-27.5pp

Other financials

Income statement

See full
Revenue--100%
Operating income-$59.3M-32.9%
Net income-$53.8M-29.3%
EPS (diluted)-$0.48+7.7%

Balance sheet

See full
Cash & equivalents$582.7M+126%
Total debt$3.7M-22.6%
Total equity$588.7M+91.7%
Total assets$619.8M+80.9%

Cash flow

See full
Operating cash flow-$58.6M-10.5%
CapEx$3.0M-18.1%
Free cash flow-$61.6M-8.7%

Valuation

See full
Market cap$2.19B+323%
Enterprise value$1.61B+470%
P/S545.2×+498×

Profitability

See full
Operating margin-5,947.9%-12,002pp
Net margin-5,593.8%-11,284pp
FCF margin-5,118.9%-8,601pp

Returns & leverage

See full
Return on equity-50.1%-10.8pp
Debt / equity0.0×
Current ratio21.7×+11.2×

Where this comes from

Calculated from Immunome’s reported figures.

Based on trailing twelve months.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's return on invested capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immunome's return on invested capital?
Immunome (IMNM) reported return on invested capital of -746.6% in Q1 2026.
What does return on invested capital mean?
Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.